JP2024542790A5 - - Google Patents
Info
- Publication number
- JP2024542790A5 JP2024542790A5 JP2024533043A JP2024533043A JP2024542790A5 JP 2024542790 A5 JP2024542790 A5 JP 2024542790A5 JP 2024533043 A JP2024533043 A JP 2024533043A JP 2024533043 A JP2024533043 A JP 2024533043A JP 2024542790 A5 JP2024542790 A5 JP 2024542790A5
- Authority
- JP
- Japan
- Prior art keywords
- vlp according
- protein
- fusion protein
- domain
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285995P | 2021-12-03 | 2021-12-03 | |
| US63/285,995 | 2021-12-03 | ||
| US202263298626P | 2022-01-11 | 2022-01-11 | |
| US63/298,626 | 2022-01-11 | ||
| US202263423372P | 2022-11-07 | 2022-11-07 | |
| US63/423,372 | 2022-11-07 | ||
| PCT/US2022/080836 WO2023102538A1 (en) | 2021-12-03 | 2022-12-02 | Self-assembling virus-like particles for delivery of prime editors and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542790A JP2024542790A (ja) | 2024-11-15 |
| JP2024542790A5 true JP2024542790A5 (https=) | 2025-12-10 |
Family
ID=84901474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533043A Pending JP2024542790A (ja) | 2021-12-03 | 2022-12-02 | プライムエディターの送達のための自己集合性ウイルス様粒子、ならびにその作製および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250064979A1 (https=) |
| EP (1) | EP4441072A1 (https=) |
| JP (1) | JP2024542790A (https=) |
| KR (1) | KR20240130159A (https=) |
| AU (1) | AU2022403015A1 (https=) |
| CA (1) | CA3239498A1 (https=) |
| GB (1) | GB2630191A (https=) |
| IL (1) | IL313146A (https=) |
| WO (1) | WO2023102538A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2025051799A1 (en) | 2023-09-05 | 2025-03-13 | Aarhus Universitet | Dna-encoded fusion proteins for incorporation of prime editing protein/rna complexes in virus-like particles |
| WO2025096936A2 (en) | 2023-11-03 | 2025-05-08 | The Broad Institute, Inc. | Use of prime editing in correcting mutations in cdkl5 |
| CN118126137A (zh) * | 2024-01-19 | 2024-06-04 | 微光基因(苏州)有限公司 | 用于递送核酸和蛋白质的类病毒样蛋白颗粒及其制备方法 |
| WO2025185623A1 (en) * | 2024-03-04 | 2025-09-12 | Shanghaitech University | Virus-like particles for gene editing |
| WO2025217616A1 (en) | 2024-04-12 | 2025-10-16 | The Broad Institute, Inc. | Prime editing and base editing of the atp1a3 gene for the treatment of alternating hemiplegia of childhood |
| WO2025248564A1 (en) * | 2024-05-30 | 2025-12-04 | Protextent Biosolutions Private Limited | A novel virus-like particle platform based on intein-mediated bioconjugation with target antigen and encapsulated with immunomodulatory factors |
| WO2025262311A1 (en) * | 2024-06-21 | 2025-12-26 | Institut National De La Sante Et De La Recherche Medicale | Methods and products for prime editing genetic engineering |
| WO2025262314A1 (en) * | 2024-06-21 | 2025-12-26 | Institut National De La Sante Et De La Recherche Medicale | Methods and products for prime editing genetic engineering |
| WO2026024856A2 (en) | 2024-07-23 | 2026-01-29 | The Broad Institute, Inc. | Compositions and methods for production of double-stranded dna in cells for programmable gene integration |
| CN121628933A (zh) * | 2024-08-30 | 2026-03-10 | 中国科学院遗传与发育生物学研究所 | 反向引导编辑系统 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5244797B1 (en) | 1988-01-13 | 1998-08-25 | Life Technologies Inc | Cloned genes encoding reverse transcriptase lacking rnase h activity |
| EP1235914A2 (en) | 1999-11-24 | 2002-09-04 | Joseph Rosenecker | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| US8178291B2 (en) | 2005-02-18 | 2012-05-15 | Monogram Biosciences, Inc. | Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors |
| US9783791B2 (en) | 2005-08-10 | 2017-10-10 | Agilent Technologies, Inc. | Mutant reverse transcriptase and methods of use |
| CN101668848B (zh) | 2007-04-26 | 2014-10-22 | 雷蒙特亚特特拉维夫大学有限公司 | 来自口腔粘膜的多能自体干细胞和使用方法 |
| US10113156B2 (en) | 2009-03-04 | 2018-10-30 | Board Of Regents, The University Of Texas System | Stabilized reverse transcriptase fusion proteins |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| DE102010025907A1 (de) | 2010-07-02 | 2012-01-05 | Robert Bosch Gmbh | Wellenenergiewandler zur Umwandlung von kinetischer Energie in elektrische Energie |
| WO2012054727A1 (en) | 2010-10-22 | 2012-04-26 | Bio-Rad Laboratories, Inc. | Reverse transcriptase mixtures with improved storage stability |
| KR102096534B1 (ko) | 2011-09-28 | 2020-04-03 | 에라 바이오테크, 에스.에이. | 분할된 인테인 및 그의 이용 |
| EP3431497B1 (en) | 2012-06-27 | 2022-07-27 | The Trustees of Princeton University | Split inteins, conjugates and uses thereof |
| DK2904101T3 (da) | 2012-10-03 | 2019-08-12 | Agrivida Inc | Intein-modificerede proteaser, fremstilling deraf og industrielle anvendelser |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| CN107075491B (zh) | 2014-10-28 | 2021-07-06 | 谷万达公司 | 用于稳定反式剪接的内含肽修饰的蛋白酶的方法和组合物 |
| WO2017068077A1 (en) * | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| US9580698B1 (en) | 2016-09-23 | 2017-02-28 | New England Biolabs, Inc. | Mutant reverse transcriptase |
| WO2020102709A1 (en) * | 2018-11-16 | 2020-05-22 | The Regents Of The University Of California | Compositions and methods for delivering crispr/cas effector polypeptides |
| WO2020191233A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US20220204975A1 (en) * | 2019-04-12 | 2022-06-30 | President And Fellows Of Harvard College | System for genome editing |
-
2022
- 2022-12-02 WO PCT/US2022/080836 patent/WO2023102538A1/en not_active Ceased
- 2022-12-02 EP EP22840541.1A patent/EP4441072A1/en active Pending
- 2022-12-02 JP JP2024533043A patent/JP2024542790A/ja active Pending
- 2022-12-02 AU AU2022403015A patent/AU2022403015A1/en active Pending
- 2022-12-02 IL IL313146A patent/IL313146A/en unknown
- 2022-12-02 CA CA3239498A patent/CA3239498A1/en active Pending
- 2022-12-02 US US18/715,587 patent/US20250064979A1/en active Pending
- 2022-12-02 GB GB2409668.7A patent/GB2630191A/en active Pending
- 2022-12-02 KR KR1020247021783A patent/KR20240130159A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542790A5 (https=) | ||
| JP2024544012A5 (https=) | ||
| Accola et al. | Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain | |
| Owens et al. | Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus | |
| Dorfman et al. | Functional domains of the capsid protein of human immunodeficiency virus type 1 | |
| Yu et al. | Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions | |
| Jacks et al. | Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. | |
| US7811578B2 (en) | Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide | |
| JP2010535495A5 (https=) | ||
| Wilk et al. | Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain | |
| EP2583974A1 (en) | Pseudotyping of foamy viruses | |
| McGettigan et al. | Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome | |
| JP2004508808A5 (https=) | ||
| Radoshitzky et al. | Ebolavirus Δ-peptide immunoadhesins inhibit Marburgvirus and Ebolavirus cell entry | |
| EP0630409B1 (en) | Defective packaging non-oncoviral vectors based on mpmv | |
| ES2683820T3 (es) | Uso de proteínas GAG no de subtipo B para encapsidación lentiviral | |
| JP3264281B2 (ja) | Ｈｉｖパッケージング配列を含むベクター、パッケージング不全ｈｉｖベクター及びその使用 | |
| Balliet et al. | Efficient infection mediated by viral receptors incorporated into retroviral particles | |
| Chen et al. | Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity | |
| Le Blanc et al. | HTLV-1 structural proteins | |
| Weiss | Retrovirus receptors on human cells | |
| Timmins et al. | Structural studies on the Ebola virus matrix protein VP40 indicate that matrix proteins of enveloped RNA viruses are analogues but not homologues | |
| AU2001292944B2 (en) | Peptide inhibitors of HIV entry | |
| JP2003517839A5 (https=) | ||
| Urban et al. | Retroviral display in gene therapy, protein engineering, and vaccine development |